Literature DB >> 31917191

Redundant role of ASK1-mediated p38MAPK activation in human platelet function.

Kamila M Sledz1, Samantha F Moore1, Vijayasameerah Vijayaragavan1, Shahida Mallah1, Lucy J Goudswaard1, Christopher M Williams1, Roger W Hunter1, Ingeborg Hers2.   

Abstract

Apoptosis signal-regulating kinase 1 (ASK1) is a member of mitogen-activated protein kinase kinase kinase (MAP3K) family, which recently has been implicated in the regulation of p38 MAPK/PLA2/thromboxane (TxA2) generation, as well as P2Y12 signalling in murine platelets. ASK1 has therefore been proposed as a potential target for anti-thrombotic therapy. At present it is unknown whether ASK1 also contributes to TxA2 formation and platelet function in human. In this study we therefore examined the role of ASK1 using the ASK1 inhibitor selonsertib (GS-4997). We established that ASK1 is responsible for p38 phosphorylation and TxA2 formation in murine platelets, with both GS4997 and p38 inhibitors reducing TxA2 formation. Similar to murine platelets, activation of human platelets resulted in the rapid and transient phosphorylation of ASK1 and the MAP2Ks MMK3/4/6. In contrast, phosphorylation of p38 and its substrate; MAPKAP-kinase2 (MAPKAPK2) was much more sustained. In keeping with these findings, inhibition of ASK1 blocked early, but not later p38/MAPKAPK2 phosphorylation. The latter was dependent on non-canonical autophosphorylation as it was blocked by the p38 inhibitor; SB203580 and the SYK inhibitor; R406. Furthermore, ASK1 and p38 inhibitors had no effect on PLA2 phosphorylation, TxA2 formation and platelet aggregation, demonstrating that this pathway is redundant in human platelets. Together, these results demonstrate that ASK1 contributes to TxA2 formation in murine, but not human platelets and highlight the importance of confirming findings from genetic murine models in humans.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31917191     DOI: 10.1016/j.cellsig.2020.109528

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  4 in total

1.  ASK1 Inhibitor in Chronic Kidney Disease Therapy: From Bench to Bedside.

Authors:  Lu Wen; Qingqing Wei
Journal:  Kidney360       Date:  2022-07-28

2.  Lumican silencing alleviates tumor necrosis factor-α-induced nucleus pulposus cell inflammation and senescence by inhibiting apoptosis signal regulating kinase 1/p38 signaling pathway via inactivating Fas ligand expression.

Authors:  Zhenqiang Li; Chengfeng Sun; Maosong Chen; Boding Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Exploring the Mechanism of Realgar against Esophageal Cancer Based on Ferroptosis Induced by ROS-ASK1-p38 MAPK Signaling Pathway.

Authors:  Ruyi Yang; Fazhang Chen; Haizhen Xu; Zhanfang Guo; Changxia Cao; Hongyan Zhang; Changrong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-12       Impact factor: 2.650

4.  Apoptosis signal-regulating kinase 1 regulates immune-mediated thrombocytopenia, thrombosis, and systemic shock.

Authors:  Pravin Patel; Noor F Shaik; Yuhang Zhou; Kalyan Golla; Steven E McKenzie; Ulhas P Naik
Journal:  J Thromb Haemost       Date:  2020-09-09       Impact factor: 5.824

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.